IRIS
DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.814
NA - Nord America 1.518
SA - Sud America 484
Continente sconosciuto - Info sul continente non disponibili 349
EU - Europa 343
AF - Africa 58
OC - Oceania 1
Totale 7.567
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 2.193
SG - Singapore 1.753
US - Stati Uniti d'America 1.374
BR - Brasile 414
CN - Cina 350
IT - Italia 219
VN - Vietnam 189
BD - Bangladesh 135
IN - India 81
CA - Canada 53
MX - Messico 45
GB - Regno Unito 33
AR - Argentina 25
IQ - Iraq 20
ZA - Sudafrica 18
JM - Giamaica 16
EC - Ecuador 14
TR - Turchia 14
DE - Germania 12
NL - Olanda 12
SA - Arabia Saudita 12
UZ - Uzbekistan 11
PL - Polonia 10
UA - Ucraina 10
CO - Colombia 9
PK - Pakistan 9
HN - Honduras 8
ID - Indonesia 8
MA - Marocco 8
RU - Federazione Russa 8
TN - Tunisia 8
ES - Italia 7
JP - Giappone 7
CL - Cile 6
CR - Costa Rica 6
FR - Francia 6
DZ - Algeria 5
ET - Etiopia 5
KE - Kenya 5
UY - Uruguay 5
VE - Venezuela 5
EG - Egitto 4
NP - Nepal 4
AT - Austria 3
AZ - Azerbaigian 3
BB - Barbados 3
JO - Giordania 3
MD - Moldavia 3
OM - Oman 3
PS - Palestinian Territory 3
PY - Paraguay 3
SE - Svezia 3
SV - El Salvador 3
AE - Emirati Arabi Uniti 2
DO - Repubblica Dominicana 2
FI - Finlandia 2
GH - Ghana 2
GT - Guatemala 2
KG - Kirghizistan 2
KR - Corea 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
NI - Nicaragua 2
PH - Filippine 2
PT - Portogallo 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BG - Bulgaria 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GF - Guiana Francese 1
GR - Grecia 1
GY - Guiana 1
HT - Haiti 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
KZ - Kazakistan 1
LY - Libia 1
MK - Macedonia 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.219
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.192
San Jose 294
Singapore 275
Council Bluffs 269
Milan 99
Santa Clara 86
Ashburn 84
Beijing 70
Ho Chi Minh City 54
Hanoi 52
New York 45
Mumbai 34
Los Angeles 31
São Paulo 30
Mexico City 24
Rome 19
Dallas 17
Dhaka 14
Orem 14
Chicago 13
Da Nang 13
Tampa 13
Bar Harbor 11
Buffalo 11
Montreal 10
Rio de Janeiro 10
Warsaw 10
Figino 9
Kingston 9
Philadelphia 9
San Pietro Vernotico 9
Tashkent 9
Baghdad 8
Atlanta 7
Biên Hòa 7
Bologna 7
London 7
Naples 7
New Delhi 7
San Francisco 7
Thái Nguyên 7
Brooklyn 6
Goiânia 6
Houston 6
Johannesburg 6
Porto Alegre 6
Salvador 6
Tokyo 6
Addis Ababa 5
Boardman 5
Brasília 5
Chennai 5
Guayaquil 5
Haiphong 5
Las Vegas 5
Miami 5
Nairobi 5
Orlando 5
Phoenix 5
Riyadh 5
San José 5
San Pedro Sula 5
Santiago 5
The Bronx 5
Toronto 5
Bari 4
Cape Town 4
Caxias do Sul 4
Charlotte 4
Chiarano 4
Columbus 4
Cotia 4
Dammam 4
Fort Lauderdale 4
Franca 4
Indpls 4
Juiz de Fora 4
Memphis 4
Piracicaba 4
Querétaro 4
Ribeirão Preto 4
Santo André 4
Sumaré 4
São Bernardo do Campo 4
Tunis 4
Uberlândia 4
Ankara 3
Asunción 3
Baku 3
Baltimore 3
Belo Horizonte 3
Boston 3
Bragança Paulista 3
Bridgetown 3
Calgary 3
Casablanca 3
Chapecó 3
Concord 3
Curitiba 3
Da Lat 3
Totale 4.156
Salva come PNG Salva come JPEG
Nome #
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 119
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 117
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity 114
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 105
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. 92
Prevention and therapy of neutropenia in elderly patients 87
Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey 85
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer 81
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 79
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial 78
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 75
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 75
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients 74
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 73
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials 69
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 67
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial 66
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 65
Adjuvant concomitant chemotherapy in pancreatic cancer. 65
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 64
Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer 63
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 63
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial 62
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 62
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone 59
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 59
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer 59
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 59
Anticancer drug delivery with nanoparticles 58
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases 58
A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study 57
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer 56
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 56
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 55
A Phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer 55
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 54
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization 54
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 52
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features 52
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 52
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT) 51
[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy. 51
Germ cell tumours of the testis 51
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma 51
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. 50
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 49
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material 48
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial 48
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 48
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 47
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger 47
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 47
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 47
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: Results from the Italian national registry 47
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. 46
Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments 45
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators 45
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 45
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer 44
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience 44
Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies 44
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 44
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer 44
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer 43
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 42
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 42
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 41
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination 41
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 41
Cell-free DNA as a diagnostic marker for cancer: current insights 41
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 41
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999 41
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 40
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 40
Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review 40
Dose intensification in hormone receptor–negative and/or human epidermal growth factor receptor 2–negative high-risk primary breast cancer. 40
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer 39
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 38
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 38
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study 38
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 37
The prognostic value of pain in castration-sensitive prostate cancer 37
High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation 36
Consider quality of life to improve quality of cancer guidelines 36
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor? 36
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 36
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 36
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer 35
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience 35
First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study 35
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party 35
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors 34
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 34
Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis 34
Immunotherapy for prostate cancer: Where we are headed 32
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial 32
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 32
Early use of abiraterone and radium-223 in metastatic prostate cancer 31
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 31
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 30
Totale 5.248
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20252.898 0 0 0 0 0 0 315 6 1.345 704 213 315
2025/20263.510 635 795 274 197 129 126 353 188 251 328 103 131
2026/20271.159 444 715 0 0 0 0 0 0 0 0 0 0
Totale 7.567